Inventiva Pharma announced the beginning of patient enrollment for its Phase IIb clinical trial (NATIVE - NASH Trial to Validate IVA337 Efficacy) evaluating the company’s lead compound, IVA337, for the treatment of Non-Alcoholic Steatohepatitis (NASH). NATIVE is a randomized, double-blind, placebo-controlled, multi-center, Phase IIb clinical trial in NASH patients. The study will investigate the safety and efficacy of two doses of IVA337 (800 and 1200 mg/day) over a 24-week period and will enroll up to 225 patients in 12 European countries. The primary endpoint will be based on histologically assessed improvement of the activity component of the SAF2 score combining inflammation and ballooning, without worsening of fibrosis.